GlassScriptPhysician profile
Khamaj I Dave
NPI 1275594657
$5,062.67
in general payments reported to CMS, 2019-2025
31 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,895 · 2020: $727 · 2021: $361 · 2022: $286 · 2023: $177 · 2024: $41.65 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $861.31 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $631.73 | 2019-2023 | Uptravi |
| Boston Scientific Corporation | $574.55 | 2019-2025 | Avvigo Guidance System, Rotapro |
| Amgen INC. | $364.55 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $350.44 | 2019-2020 | |
| Abbott Laboratories | $243.93 | 2019-2023 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $235.92 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $234.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $197.78 | 2019 | |
| Medtronic Vascular, INC. | $176.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $169.54 | 2019-2020 | |
| Acist Medical Systems, INC. | $166.62 | 2020 | |
| Amarin Pharma, INC. | $135.22 | 2019-2020 | |
| Gilead Sciences, INC. | $107.91 | 2019 | |
| Pfizer INC. | $94.33 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $83.44 | 2019-2020 | |
| Baxter Healthcare | $76.85 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Medtronic, INC. | $60.32 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.24 | 2019 | |
| Philips North America LLC | $39.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.50 | 2019 | |
| Lundbeck LLC | $25.00 | 2019 | |
| Bardy Diagnostics, INC. | $25.00 | 2022 | |
| Novo Nordisk INC | $23.80 | 2024 | Rybelsus, Ozempic |
| Angiodynamics, INC. | $19.54 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.81 | 2019 | |
| Scpharmaceuticals INC. | $17.85 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.67 | 2019 | |
| Heartflow, INC. | $15.71 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.98 | 2019 | |
| Cardiovascular Systems INC. | $5.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khamaj Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.